Huons Global휴온스글로벌
084110 · KOSDAQ · ₩084110 · 휴온스글로벌
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩77,093
vs the current price (₩21,950)
- Enterprise value
- ₩1.6T
- Equity value
- ₩976B
- WACC
- 6.4%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model is 251% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:
- To match today's price of ₩21,950, the model needs an operating margin of 8.0% every year (it uses 12.1%).
- Or revenue growth −14.7 points a year higher than assumed in each of the 5 years.
- Today's P/E is 12.3× against a typical 16.6× over the last 10 years.
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- ₩22,502
- +2.5%
- Base
- ₩77,093
- +251.2%
- Bull
- ₩177,461
- +708.5%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (12.1%).
Revenue growth
- 8.5%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (8.5% a year, annual reports), fading to 3% by year 5.
- 7.1%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (8.5% a year, annual reports), fading to 3% by year 5.
- 5.7%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (8.5% a year, annual reports), fading to 3% by year 5.
- 4.4%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (8.5% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (8.5% a year, annual reports), fading to 3% by year 5.
Business
- 12.1%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 8.9%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 11.2%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 26.3%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.03%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-27.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.18, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.53%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩847B
- Net debt (borrowings and leases − cash and deposits)
- ₩106B
- + Stakes and investments
- ₩7.7B
- Associates, long-term financial assets and deposits (book value)
- − Minority interests
- ₩534B
- Shares
- 12,659,812
- Share price
- ₩21,950
- Market cap
- ₩278B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩758B | ₩813B | ₩847B | ₩919B | ₩984B | ₩1T | ₩1.1T | ₩1.1T |
| Growth | 14.2% | 7.3% | 4.2% | 8.5% | 7.1% | 5.7% | 4.4% | 3.0% |
| EBIT | ₩114B | ₩97B | ₩91B | ₩111B | ₩119B | ₩126B | ₩131B | ₩135B |
| EBIT margin | 15.0% | 11.9% | 10.7% | 12.1% | 12.1% | 12.1% | 12.1% | 12.1% |
| After-tax EBIT | ₩83B | ₩70B | ₩66B | ₩81B | ₩86B | ₩91B | ₩95B | ₩98B |
| + Depreciation | — | — | — | ₩82B | ₩88B | ₩93B | ₩97B | ₩100B |
| − Capital spending | ₩81B | ₩136B | ₩52B | ₩103B | ₩110B | ₩116B | ₩122B | ₩125B |
| − Working capital | −₩17B | ₩36B | ₩115B | ₩19B | ₩17B | ₩15B | ₩12B | ₩8.6B |
| Free cash flow | — | — | — | ₩41B | ₩47B | ₩53B | ₩58B | ₩64B |
| Discount factor | — | — | — | 0.940 | 0.883 | 0.830 | 0.780 | 0.733 |
| Present value | — | — | — | ₩38B | ₩41B | ₩44B | ₩45B | ₩47B |
Terminal value ₩1.9T, worth ₩1.4T today: 87% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩43,765 a share)Now 0.50× | ₩21,6990.50× | ₩27,0540.62× | ₩53,3711.22× |
| Price / earnings (last 12 months: ₩1,783 a share)Now 12.3× | ₩12,7117.13× | ₩29,51716.6× | ₩62,55635.1× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 5.4% | ₩85,876 | ₩99,349 | ₩116,744 | ₩140,080 | ₩173,052 |
| 5.9% | ₩71,086 | ₩81,420 | ₩94,372 | ₩111,095 | ₩133,529 |
| 6.4% | ₩59,050 | ₩67,162 | ₩77,093 | ₩89,541 | ₩105,612 |
| 6.9% | ₩49,068 | ₩55,558 | ₩63,352 | ₩72,893 | ₩84,852 |
| 7.4% | ₩40,660 | ₩45,934 | ₩52,167 | ₩59,652 | ₩68,816 |
Now (TTM)
- Market cap
- ₩278B
- Enterprise value
- ₩380B
- P/E
- 12.3×
- P/B
- 0.5×
- P/S
- 0.3×
- EV/EBITDA
- —
- Dividend yield
- 4.0%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩51,200 | ₩43,250 | ₩23,650 | ₩18,750 | ₩38,500 |
| Market cap | ₩648B | ₩548B | ₩299B | ₩237B | ₩487B |
| P/E | 22.5× | 21.2× | 7.8× | — | 122.0× |
| P/B | 1.2× | 1.1× | 0.6× | 0.5× | 0.9× |
| P/S | 0.8× | 0.7× | 0.4× | 0.4× | 0.8× |
| EV/EBITDA | — | — | — | — | — |
| Dividend yield | 1.7% | 1.2% | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Huons Global | 12.3× | 0.5× | 0.3× | — | 4.0% |
| Samsung Biologics | 32.1× | 7.6× | 14.0× | — | 0.0% |
| Celltrion | 27.8× | 2.4× | 8.9× | — | 0.0% |
| Alteogen | 78.8× | 28.4× | 59.9× | — | 0.1% |
| Yuhan | 24.8× | 2.5× | 2.6× | 32.5× | 0.8% |
| SK biopharmaceuticals | 14.6× | 5.7× | 6.8× | — | 0.0% |
| HLB | — | 15.4× | 54.6× | — | 0.0% |
| Similar companies (median) | 27.8× | 6.7× | 11.5× | 32.5× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Huons Global / 휴온스글로벌 / 084110 / KRX:084110
Source: KRX statistical information